Phase
Condition
Non-hodgkin's Lymphoma
Cancer/tumors
White Cell Disorders
Treatment
Idecabtagene vicleucel
Lisocabtagene maraleucel
Clinical Study ID
All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Participant has received a commercially available Bristol-Myers Squibb (BMS)manufactured Gene Modified Cell Therapy (GMCT) and has been diagnosed with aqualifying second primary malignancy or a second primary malignancy which BMS hasqualified for testing.
Participant has received a commercially available BMS manufactured GMCT in aclinical trial or other investigational setting (including non-conforming product)for which there is no testing protocol in place for that trial or investigationalsetting and has been diagnosed with a qualifying second primary malignancy or asecond primary malignancy which BMS has qualified for testing.
Exclusion
Exclusion Criteria:
Participant is actively participating in a clinical trial where information andsample collection is being conducted under that clinical trial.
Participant has not received a BMS manufactured GMCT or has not been diagnosed witha qualifying second primary malignancy.
Study Design
Connect with a study center
CellCarta
Antwerp,
BelgiumSite Not Available
Universitaetsklinikum Essen (AoR)
Essen, 45147
GermanyActive - Recruiting
Kumamoto University
Kumamoto-city, Kumamoto 8608556
JapanActive - Recruiting
Local Institution - 0003
Kumamoto-city, Kumamoto 8608556
JapanSite Not Available
Kantonsspital Aarau
Aarau, 5001
SwitzerlandActive - Recruiting
Bristol-Myers Squibb
Boudry,
SwitzerlandSite Not Available
Local Institution - 0010
Salt Lake City, Utah 84112
United StatesSite Not Available
Local Institution - 0004
Madison, Wisconsin 53792
United StatesSite Not Available
University Of Wisconsin
Madison, Wisconsin 53792
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.